EUVIMEDEUVIMED entdecken
Crossref

Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study

Onyebuchi Ononogbu, Oyinkansola Akindele, Sahar Yazdanfard, Bilqees Fatima, Susan Abughosh, Meghana V Trivedi

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08619-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Onyebuchi Ononogbu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX, USA. ojononog@central.uh.edu. Hauptthemen laut MEDLINE: Multiple Myeloma, Thalidomide, Social Class, Lenalidomide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: NIMHD NIH HHS, National Institute on Minority Health and Health Disparities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Poor adherence to oral chemotherapy adversely impacts clinical outcomes and escalates overall healthcare costs. Despite barriers to medication adherence, a significant gap remains in assessing adherence to oral chemotherapy among multiple myeloma (MM) patients with lower socioeconomic status. Hence, our study aims to evaluate immunomodulator adherence in MM patients at a county hospital, primarily serving underrepresented and indigent individuals with low socioeconomic status across the greater Houston area. METHODS: Inclusion criteria composed of patients diagnosed with MM, aged at least 18 years, and treated with lenalidomide or pomalidomide-two widely used immunomodulators-for a minimum of 2 months or having two or more records of dispensation between May 2019 and May 2021. Adherence was gauged using an adjusted version of the medication possession ratio (MPR). RESULTS: Sixty-two patients were enrolled, yielding a mean MPR value of 88% (SD, ± 18.9). Of these, 43 patients (69.3%) demonstrated adherence with an MPR of ≥ 0.90. A significant difference was found in treatment duration between the adherent (mean 8.8 months; SD, ± 7.2) and non-adherent (mean 13.4 months; SD, ± 7.9) groups (p = 0.027). Notably, race/ethnicity demonstrated a significant difference (p = 0.048), driven by disparities in African American and Hispanic representation across adherence levels. CONCLUSION: In summary, our findings highlight race and treatment duration to be predictors of immunomodulator adherence among MM patients with lower socioeconomic status. Further research is imperative to devise and test innovative interventions aimed at enhancing medication adherence, thereby contributing to improved survival and healthcare quality in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaThalidomideSocial ClassLenalidomideDrug MonitoringHumansMaleRetrospective StudiesFemaleMiddle AgedAgedImmunologic FactorsImmunomodulating AgentsTexasAged, 80 and overAdult

Stichwörter der Autor:innen

AdherenceImmunomodulatorsIndigentMultiple myelomaUnderrepresented

Substanzen

ThalidomidepomalidomideLenalidomideImmunologic FactorsImmunomodulating Agents

Autor:innen und Institutionen

  • Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX, USA. ojononog@central.uh.edu.
  • Harris Health System, Houston, TX, USA.
  • Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX, USA.
  • Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA.

Förderung

  • NIMHD NIH HHS
  • National Institute on Minority Health and Health Disparities

Zitieren

APA

Ononogbu, O., Akindele, O., Yazdanfard, S., Fatima, B., Abughosh, S., & Trivedi, M. V. (2024). Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08619-8

Vancouver

Ononogbu O, Akindele O, Yazdanfard S, Fatima B, Abughosh S, Trivedi MV. Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08619-8

BibTeX
@article{Ononogbu2024,
  author = {Ononogbu, Onyebuchi and Akindele, Oyinkansola and Yazdanfard, Sahar and Fatima, Bilqees and Abughosh, Susan and Trivedi, Meghana V},
  title = {Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08619-8}
}
Kostenlos starten →